Suppressive Effects of Vascular Endothelial Growth Factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Albrecht, Imke ^a   Kopfstein, Lucie ^a   Strittmatter, Karin ^b   Schomber, Tibor ^a   Falkevall, Annelie ^d,e   Hagberg, Carolina E ^d,e   Lorentz, Pascal ^a   Jeltsch, Michael ^c   Alitalo, Kari ^c   Eriksson, Ulf ^d,e   Christofori, Gerhard ^a   Pietras, Kristian ^d  

^a UNIVERSITY OF BASEL   (Switzerland)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HELSINKI   (Finland)

^d KAROLINSKA INSTITUTE   (Sweden)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; GENE DELETION; GENE DOSAGE; HISTOPATHOLOGY; HOMOZYGOSITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; C57BL MOUSE; DISEASE MODEL; FEMALE; GENETICS; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); NEUROENDOCRINE TUMOR; PANCREAS; PANCREAS TUMOR; PATHOLOGY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; VASCULARIZATION;

MUS; MUS MUSCULUS;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; PANCREAS; PANCREATIC NEOPLASMS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR B;

EID: 78649655419     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014109     Document Type: Article

References (51)

1. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438: 932-936.
2. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
3. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439.
4. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, et al. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442.
5. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, et al. (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463-475.
6. Karpanen T, Alitalo K (2008) Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol 3: 367-397.
7. Petrova TV, Bono P, Holnthoner W, Chesnes J, Pytowski B, et al. (2008) VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. Cancer Cell 13: 554-556.
8. Fischer C, Mazzone M, Jonckx B, Carmeliet P (2008) FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8: 942-956.
9. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, et al. (1996) Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A 93: 2576-2581.
10. Lahteenvuo JE, Lahteenvuo MT, Kivela A, Rosenlew C, Falkevall A, et al. (2009) Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor- 1- and neuropilin receptor-1-dependent mechanisms. Circulation 119: 845-856.
11. Aase K, von Euler G, Li X, Ponten A, Thoren P, et al. (2001) Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation 104: 358-364.
12. Bellomo D, Headrick JP, Silins GU, Paterson CA, Thomas PS, et al. (2000) Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res 86: E29-35.
13. Hagberg CE, Falkevall A, Wang X, Larsson E, Huusko J, et al. (2010) Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 464: 917-921.
14. Gunningham SP, Currie MJ, Han C, Robinson BA, Scott PA, et al. (2001) VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. J Pathol 193: 325-332.
15. Gunningham SP, Currie MJ, Han C, Turner K, Scott PA, et al. (2001) Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res 61: 3206-3211.
16. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, et al. (2003) The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGFB, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 200: 183-194.
17. Mylona E, Alexandrou P, Giannopoulou I, Liapis G, Sofia M, et al. (2007) The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma. Gynecol Oncol 104: 557-563.
18. Kawakami M, Furuhata T, Kimura Y, Yamaguchi K, Hata F, et al. (2003) Expression analysis of vascular endothelial growth factors and their relationships to lymph node metastasis in human colorectal cancer. J Exp Clin Cancer Res 22: 229-237.
19. Shintani S, Li C, Ishikawa T, Mihara M, Nakashiro K, et al. (2004) Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. Oral Oncol 40: 13-20.
20. Hanahan D (1985) Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315: 115-122.
21. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D (2002) VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1: 193-202.
22. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-812.
23. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287-1295.
24. Pietras K, Hanahan D (2005) A multitargeted, metronomic, and maximumtolerated dose "chemo-switch'' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23: 939-952.
25. Compagni A, Wilgenbus P, Impagnatiello MA, Cotten M, Christofori G (2000) Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 60: 7163-7169.
26. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309.
27. Cunha SI, Pardali E, Thorikay M, Anderberg C, Hawinkels L, et al. (2010) Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med 207: 85-100.
28. Efrat S, Linde S, Kofod H, Spector D, Delannoy M, et al. (1988) Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene. Proc Natl Acad Sci U S A 85: 9037-9041.
29. Li Y, Zhang F, Nagai N, Tang Z, Zhang S, et al. (2008) VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J Clin Invest 118: 913-923.
30. Hagberg C, Falkevall A, Wang X, Larsson E, Huusko J, et al. (2010) Vascular Endothelial Growth Factor B controls endothelial fatty acid uptake. Nature 464: 917-921.
31. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, et al. (2001) Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97: 785-791.
32. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, et al. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 438: 820-827.
33. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744.
34. Nozawa H, Chiu C, Hanahan D (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 103: 12493-12498.
35. Gannon G, Mandriota SJ, Cui L, Baetens D, Pepper MS, et al. (2002) Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during beta-cell carcinogenesis. Cancer Res 62: 603-608.
36. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141: 178-190.
37. Schomber T, Kopfstein L, Djonov V, Albrecht I, Baeriswyl V, et al. (2007) Placental growth factor-1 attenuates vascular endothelial growth factor-A dependent tumor angiogenesis during beta cell carcinogenesis. Cancer Res 67: 10840-10848.
38. Olofsson B, Pajusola K, von Euler G, Chilov D, Alitalo K, et al. (1996) Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J Biol Chem 271: 19310-19317.
39. Eriksson A, Cao R, Pawliuk R, Berg SM, Tsang M, et al. (2002) Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 1: 99-108.
40. Makinen T, Olofsson B, Karpanen T, Hellman U, Soker S, et al. (1999) Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem 274: 21217-21222.
41. Serini G, Maione F, Giraudo E, Bussolino F (2009) Semaphorins and tumor angiogenesis. Angiogenesis 12: 187-193.
42. Kusminski CM, Shetty S, Orci L, Unger RH, Scherer PE (2009) Diabetes and apoptosis: lipotoxicity. Apoptosis 14: 1484-1495.
43. Shimabukuro M, Ohneda M, Lee Y, Unger RH (1997) Role of nitric oxide in obesity-induced beta cell disease. J Clin Invest 100: 290-295.
44. Warburg O (1956) On the origin of cancer cells. Science 123: 309-314.
45. Strauss LG, Koczan D, Klippel S, Pan L, Cheng C, et al. (2008) Impact of angiogenesis-related gene expression on the tracer kinetics of 18F-FDG in colorectal tumors. J Nucl Med 49: 1238-1244.
46. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
47. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
48. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
49. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591.
50. Labosky PA, Barlow DP, Hogan BL (1994) Embryonic germ cell lines and their derivation from mouse primordial germ cells. Ciba Found Symp 182: 157-168; discussion 168-178.
51. Ohzato H, Gotoh M, Monden M, Dono K, Kanai T, et al. (1991) Improvement in islet yield from a cold-preserved pancreas by pancreatic ductal collagenase distention at the time of harvesting. Transplantation 51: 566-570.